These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34525181)

  • 1. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
    Tedeschi A; Frustaci AM; Mauro FR; Chiarenza A; Coscia M; Ciolli S; Reda G; Laurenti L; Varettoni M; Murru R; Baratè C; Sportoletti P; Greco A; Borella C; Rossi V; Deodato M; Biagi A; Zamprogna G; Pelle AC; Lapietra G; Vitale C; Morelli F; Cassin R; Fresa A; Cavalloni C; Postorino M; Ielo C; Cairoli R; Di Raimondo F; Montillo M; Del Poeta G
    Blood Adv; 2021 Dec; 5(24):5490-5500. PubMed ID: 34525181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
    Frustaci AM; Del Poeta G; Visentin A; Sportoletti P; Fresa A; Vitale C; Murru R; Chiarenza A; Sanna A; Mauro FR; Reda G; Gentile M; Varettoni M; Baratè C; Borella C; Greco A; Deodato M; Zamprogna G; Laureana R; Cipiciani A; Galitzia A; Curto Pelle A; Morelli F; Malvisi L; Coscia M; Laurenti L; Trentin L; Montillo M; Cairoli R; Tedeschi A
    Ther Adv Hematol; 2022; 13():20406207221127550. PubMed ID: 36246422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
    Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
    [No Abstract]   [Full Text] [Related]  

  • 4. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
    Gordon MJ; Churnetski M; Alqahtani H; Rivera X; Kittai A; Amrock SM; James S; Hoff S; Manda S; Spurgeon SE; Choi M; Cohen JB; Persky D; Danilov AV
    Cancer; 2018 Aug; 124(15):3192-3200. PubMed ID: 29797667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data.
    Tombak A; Pepedil Tanrıkulu F; Durusoy SS; Dinçyürek HD; Kaya E; Ümit EG; Yavaşoğlu İ; Mehtap Ö; Deveci B; Özcan MA; Terzi H; Okay M; Sayınalp N; Yılmaz M; Okan V; Kızıklı A; Özcan Ö; Çetin G; Demircioğlu S; Aydoğdu İ; Saydam G; Davulcu EA; İlhan G; Uçar MA; Özet G; Akpınar S; Turgut B; Berber İ; Kurtoğlu E; Sönmez M; Batur DS; Yıldırım R; Özkocamaz V; Güneş AK; Sahip B; Ertop Ş; Akay OM; Baştürk A; Doğu MH; Akdeniz A; Ünal A; Seyhanlı A; Gürkan E; Çekdemir D; Ferhanoğlu B
    Turk J Haematol; 2021 Dec; 38(4):273-285. PubMed ID: 34448556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
    Martino EA; Mauro FR; Reda G; Laurenti L; Visentin A; Frustaci A; Vigna E; Pepe S; Catania G; Loseto G; Murru R; Chiarenza A; Sportoletti P; Del Principe MI; Laureana R; Coscia M; Galimberti S; Ferretti E; Zucchetto A; Bomben R; Polesel J; Tedeschi A; Rossi D; Trentin L; Neri A; Morabito F; Gattei V; Gentile M
    Hematol Oncol; 2024 Jan; 42(1):e3249. PubMed ID: 38287529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib dose modifications in the management of CLL.
    Hardy-Abeloos C; Pinotti R; Gabrilove J
    J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
    Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; Arguiñano Pérez JM; Berruezo MJ; Oliveira A; Hernández-Rivas JÁ; García Malo MD; Medina Á; García Martin P; Osorio S; Baltasar P; Fernández-Zarzoso M; Marco F; Vidal Manceñido MJ; Smucler Simonovich A; López Rubio M; Jarque I; Suarez A; Fernández Álvarez R; Lancharro Anchel A; Ríos E; Losada Castillo MDC; Pérez Persona E; García Muñoz R; Ramos R; Yáñez L; Bello JL; Loriente C; Acha D; Villanueva M
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e985-e999. PubMed ID: 34511320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes in Patients with Multi-Hit
    Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
    Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
    Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
    Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
    Kittai AS; Miller C; Goldstein D; Huang Y; Abruzzo LV; Beckwith K; Bhat SA; Bond DA; Grever MR; Heerema NA; Rogers KA; Ruppert AS; Byrd JC; Woyach JA
    Blood; 2021 Dec; 138(23):2372-2382. PubMed ID: 34314481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
    JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Allan JN; Shanafelt T; Wiestner A; Moreno C; O'Brien SM; Li J; Krigsfeld G; Dean JP; Ahn IE
    Br J Haematol; 2022 Feb; 196(4):947-953. PubMed ID: 34865212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
    Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.